Prediction of factor Xa inhibitors by machine learning methods.
暂无分享,去创建一个
H H Lin | L Y Han | Y Xue | C W Yap | Y Z Chen | X H Liu | F Zhu | Y. Z. Chen | F. Zhu | C. Yap | L. Y. Han | H. H. Lin | H. Lin | Y. Xue | X. Liu | Ying Xue | Lianyi Han | C. W. Yap | Yu Zong Chen | Xianghui Liu | Feng Zhu
[1] J E Roulston,et al. Screening with tumor markers , 2002, Molecular biotechnology.
[2] Y Xue,et al. Prediction of torsade-causing potential of drugs by support vector machine approach. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.
[3] D. Fairlie,et al. Protease inhibitors: current status and future prospects. , 2000, Journal of medicinal chemistry.
[4] P. Lam,et al. Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. , 2001, Journal of medicinal chemistry.
[5] J. A. Kyle,et al. N(2)-Aroylanthranilamide inhibitors of human factor Xa. , 2000, Journal of medicinal chemistry.
[6] Vladimir N. Vapnik,et al. The Nature of Statistical Learning Theory , 2000, Statistics for Engineering and Information Science.
[7] Christopher J. C. Burges,et al. A Tutorial on Support Vector Machines for Pattern Recognition , 1998, Data Mining and Knowledge Discovery.
[8] J. A. Kyle,et al. Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity. , 2000, Journal of Medicinal Chemistry.
[9] H Martin,et al. The design of phenylglycine containing benzamidine carboxamides as potent and selective inhibitors of factor Xa. , 2001, Bioorganic & medicinal chemistry letters.
[10] D M Wallace,et al. The Efficacy and Safety of Oral Anticoagulation in Patients with Cancer , 1995, Thrombosis and Haemostasis.
[11] C. Dominguez,et al. The de novo design and synthesis of cyclic urea inhibitors of factor Xa: initial SAR studies. , 1998, Bioorganic & medicinal chemistry letters.
[12] Wei Xu,et al. Design, synthesis, and activity of a novel series of factor Xa inhibitors: optimization of arylamidine groups. , 2002, Journal of medicinal chemistry.
[13] Thomas Hofmann,et al. Predicting CNS Permeability of Drug Molecules: Comparison of Neural Network and Support Vector Machine Algorithms , 2002, J. Comput. Biol..
[14] P. Sprengeler,et al. Neutral inhibitors of the serine protease factor Xa. , 2001, Bioorganic & medicinal chemistry letters.
[15] Donald F. Specht,et al. Probabilistic neural networks , 1990, Neural Networks.
[16] R. Knabb,et al. Preparation of meta-amidino-N,N-disubstituted anilines as potent inhibitors of coagulation factor Xa. , 1998, Bioorganic & Medicinal Chemistry Letters.
[17] Takako Aizawa,et al. Quantitative structure-activity relationships for estrogen receptor binding affinity of phenolic chemicals. , 2003, Water research.
[18] D L Cheney,et al. Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa. , 1999, Journal of medicinal chemistry.
[19] A. Olson,et al. Modelling of Factor Xa‐inhibitor complexes: a computational flexible docking approach , 1999, Proteins.
[20] M. Whitlow,et al. Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa. , 1998, Journal of medicinal chemistry.
[21] Angela Smallwood,et al. SAR and factor IXa crystal structure of a dual inhibitor of factors IXa and Xa. , 2004, Bioorganic & medicinal chemistry letters.
[22] K. Ishikawa,et al. Rational design, synthesis, and structure-activity relationships of novel factor Xa inhibitors: (2-substituted-4-amidinophenyl)pyruvic and -propionic acids. , 2003, Journal of medicinal chemistry.
[23] R. Huber,et al. Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase. , 1998, Journal of medicinal chemistry.
[24] C. Dunwiddie,et al. Optimization of the beta-aminoester class of factor Xa inhibitors. Part 1: P(4) and side-chain modifications for improved in vitro potency. , 2002, Bioorganic & medicinal chemistry letters.
[25] Sayan Mukherjee,et al. Choosing Multiple Parameters for Support Vector Machines , 2002, Machine Learning.
[26] Z. R. Li,et al. Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. , 2006, Journal of molecular graphics & modelling.
[27] Jason Weston,et al. Gene Selection for Cancer Classification using Support Vector Machines , 2002, Machine Learning.
[28] Xin Chen,et al. Effect of Molecular Descriptor Feature Selection in Support Vector Machine Classification of Pharmacokinetic and Toxicological Properties of Chemical Agents , 2004, J. Chem. Inf. Model..
[29] R. Knabb,et al. Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics. , 2000, The Journal of pharmacology and experimental therapeutics.
[30] R. Knabb,et al. Isoxazolines and isoxazoles as factor Xa inhibitors. , 2000, Bioorganic & Medicinal Chemistry Letters.
[31] J. F. Wang,et al. Prediction of P-Glycoprotein Substrates by a Support Vector Machine Approach , 2004, J. Chem. Inf. Model..
[32] M. Myers,et al. Nonbenzamidine compounds as selective factor Xa inhibitors. , 2000, Bioorganic & medicinal chemistry letters.
[33] Hans Matter,et al. Design and quantitative structure-activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa. , 2002, Journal of medicinal chemistry.
[34] R. Bentley,et al. Synthesis, SAR and in vivo activity of novel thienopyridine sulfonamide pyrrolidinones as factor Xa inhibitors. , 1999, Bioorganic & medicinal chemistry letters.
[35] Andrew C. Good,et al. Measuring CAMD technique performance: A virtual screening case study in the design of validation experiments , 2004, J. Comput. Aided Mol. Des..
[36] M. Taha,et al. Ligand-based assessment of factor Xa binding site flexibility via elaborate pharmacophore exploration and genetic algorithm-based QSAR modeling. , 2005, European journal of medicinal chemistry.
[37] Y. Z. Chen,et al. Quantitative Structure-Pharmacokinetic Relationships for drug distribution properties by using general regression neural network. , 2005, Journal of pharmaceutical sciences.
[38] F. Sanz,et al. Anchor-GRIND: filling the gap between standard 3D QSAR and the GRid-INdependent descriptors. , 2005 .
[39] J. Maraganore,et al. Thrombin-specific inhibition by and slow cleavage of hirulog-1. , 1992, The Biochemical journal.
[40] Cesare Furlanello,et al. An accelerated procedure for recursive feature ranking on microarray data , 2003, Neural Networks.
[41] John M. Barnard,et al. Chemical Similarity Searching , 1998, J. Chem. Inf. Comput. Sci..
[42] Y. Ru,et al. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors. , 1998, Journal of medicinal chemistry.
[43] Roberto Todeschini,et al. Handbook of Molecular Descriptors , 2002 .
[44] K. Grandien,et al. Printed in U.S.A. Copyright © 1997 by The Endocrine Society Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors � and � , 2022 .
[45] M. Morrissey,et al. Design, synthesis, and biological activity of novel purine and bicyclic pyrimidine factor Xa inhibitors. , 1998, Bioorganic & medicinal chemistry letters.
[46] Thierry Langer,et al. Pharmacophore Identification, in Silico Screening, and Virtual Library Design for Inhibitors of the Human Factor Xa , 2005, J. Chem. Inf. Model..
[47] A. Spada,et al. Amido-(propyl and allyl)-hydroxybenzamidines: development of achiral inhibitors of factor Xa. , 2000, Bioorganic & medicinal chemistry letters.
[48] Weida Tong,et al. Phytoestrogens and mycoestrogens bind to the rat uterine estrogen receptor. , 2002, The Journal of nutrition.
[49] Brian Carnahan,et al. Comparing Statistical and Machine Learning Classifiers: Alternatives for Predictive Modeling in Human Factors Research , 2003, Hum. Factors.
[50] Juan J Perez,et al. Managing molecular diversity. , 2005, Chemical Society reviews.
[51] E. Parzen. On Estimation of a Probability Density Function and Mode , 1962 .
[52] K. Roy,et al. QSAR of human factor Xa inhibitor N2-aroylanthranilamides using principal component factor analysis. , 2002, Drug design and discovery.
[53] B. Matthews. Comparison of the predicted and observed secondary structure of T4 phage lysozyme. , 1975, Biochimica et biophysica acta.
[54] Marta Murcia,et al. Virtual screening with flexible docking and COMBINE-based models. Application to a series of factor Xa inhibitors. , 2004, Journal of medicinal chemistry.
[55] Yu Zong Chen,et al. Prediction of Cytochrome P450 3A4, 2D6, and 2C9 Inhibitors and Substrates by Using Support Vector Machines , 2005, J. Chem. Inf. Model..
[56] Richard A. Johnson,et al. Applied Multivariate Statistical Analysis , 1983 .
[57] Z R Li,et al. Prediction of genotoxicity of chemical compounds by statistical learning methods. , 2005, Chemical research in toxicology.
[58] Bernard F. Buxton,et al. Support Vector Machines in Combinatorial Chemistry , 2001 .
[59] Sulfonamidopyrrolidinone factor Xa inhibitors: potency and selectivity enhancements via P-1 and P-4 optimization. , 1999 .
[60] Michael K. Gilson,et al. Virtual Screening of Molecular Databases Using a Support Vector Machine , 2005, J. Chem. Inf. Model..
[61] Y. Matsumoto,et al. Antithrombotic effect of YM-75466 is separated from its effect on bleeding time and coagulation time. , 1998, European journal of pharmacology.
[62] B. Furie,et al. The molecular basis of blood coagulation , 1988, Cell.
[63] Peter C Jurs,et al. Predicting the genotoxicity of polycyclic aromatic compounds from molecular structure with different classifiers. , 2003, Chemical research in toxicology.
[64] Bernard F. Buxton,et al. Drug Design by Machine Learning: Support Vector Machines for Pharmaceutical Data Analysis , 2001, Comput. Chem..
[65] M. Whitlow,et al. Design, synthesis, and in vitro biological activity of indole-based factor Xa inhibitors. , 2000, Bioorganic & medicinal chemistry letters.
[66] D. Case,et al. Design and synthesis of highly constrained factor Xa inhibitors: amidine-substituted bis(benzoyl)--diazepan-2-ones and bis(benzylidene)-bis(gem-dimethyl)cycloketones. , 2003, Bioorganic & medicinal chemistry.
[67] Hans Matter,et al. Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography. , 2005, Journal of medicinal chemistry.
[68] J. Ross Quinlan,et al. C4.5: Programs for Machine Learning , 1992 .
[69] D. R. Holland,et al. Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa. , 2004, Journal of medicinal chemistry.
[70] Igor V. Pletnev,et al. Drug Discovery Using Support Vector Machines. The Case Studies of Drug-likeness, Agrochemical-likeness, and Enzyme Inhibition Predictions , 2003, J. Chem. Inf. Comput. Sci..
[71] K. Eagen,et al. Design, synthesis, and biological activity of novel factor Xa inhibitors: 4-aryloxy substituents of 2,6-diphenoxypyridines. , 2002, Bioorganic & medicinal chemistry.
[72] Nello Cristianini,et al. Support vector machine classification and validation of cancer tissue samples using microarray expression data , 2000, Bioinform..
[73] M. Whitlow,et al. Synthesis, characterization, and structure-activity relationships of amidine-substituted (bis)benzylidene-cycloketone olefin isomers as potent and selective factor Xa inhibitors. , 1999, Journal of medicinal chemistry.
[74] H. Yu,et al. Discovering compact and highly discriminative features or combinations of drug activities using support vector machines , 2003, Computational Systems Bioinformatics. CSB2003. Proceedings of the 2003 IEEE Bioinformatics Conference. CSB2003.
[75] M. Whitlow,et al. Design, synthesis, and in vitro biological activity of benzimidazole based factor Xa inhibitors. , 2000, Bioorganic & medicinal chemistry letters.
[76] N. Haginoya,et al. Design, synthesis, and biological activity of non-amidine factor Xa inhibitors containing pyridine N-oxide and 2-carbamoylthiazole units. , 2004, Bioorganic & medicinal chemistry.
[77] D. Hadjipavlou-Litina,et al. Current trends in quantitative structure activity relationships on FXa inhibitors: Evaluation and comparative analysis , 2004, Medicinal research reviews.
[78] G Klebe,et al. Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. , 1999, Journal of medicinal chemistry.
[79] K. Roy,et al. QSAR with electrotopological state atom index: human factor Xa inhibitor N2-aroylanthranilamides. , 2002, Drug design and discovery.
[80] P. Labute. A widely applicable set of descriptors. , 2000, Journal of molecular graphics & modelling.
[81] Pierre Baldi,et al. Assessing the accuracy of prediction algorithms for classification: an overview , 2000, Bioinform..
[82] György M Keseru,et al. A neural network based virtual screening of cytochrome P450 3A4 inhibitors. , 2002, Bioorganic & medicinal chemistry letters.
[83] Jens Sadowski,et al. Comparison of Support Vector Machine and Artificial Neural Network Systems for Drug/Nondrug Classification , 2003, J. Chem. Inf. Comput. Sci..
[84] B. Katz,et al. Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and factor Xa. , 2001, Journal of medicinal chemistry.
[85] J R Pruitt,et al. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1. , 1999, Journal of medicinal chemistry.
[86] Bernard De Baets,et al. Feature subset selection for splice site prediction , 2002, ECCB.
[87] A. Spada,et al. Crystal structures of human factor Xa complexed with potent inhibitors. , 2000, Journal of medicinal chemistry.
[88] T. Cacoullos. Estimation of a multivariate density , 1966 .
[89] W. Bode,et al. Design of benzamidine-type inhibitors of factor Xa. , 1998, Journal of medicinal chemistry.
[90] Daniel L Cheney,et al. Optimization of the beta-aminoester class of factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective inhibitor with excellent In vivo anticoagulant activity. , 2002, Bioorganic & medicinal chemistry letters.
[91] G. Broze. Tissue factor pathway inhibitor and the current concept of blood coagulation , 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[92] R. Czerminski,et al. Use of Support Vector Machine in Pattern Classification: Application to QSAR Studies , 2001 .
[93] C. Dominguez,et al. Design, synthesis, and biological evaluation of potent and selective amidino bicyclic factor Xa inhibitors. , 2000, Journal of medicinal chemistry.
[94] R. Snyder,et al. Assessment of the sensitivity of the computational programs DEREK, TOPKAT, and MCASE in the prediction of the genotoxicity of pharmaceutical molecules , 2004, Environmental and molecular mutagenesis.
[95] W D Shrader,et al. Development of potent and selective factor Xa inhibitors. , 2001, Bioorganic & medicinal chemistry letters.